U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303894) titled 'A Study of Isoquercetin in People With Ovarian Cancer' on Dec. 23.
Brief Summary: The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.
Study Start Date: Jan. 31, 2026
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Epithelial Ovarian Cancer
Serous Ovarian Tumor
Intervention:
DRUG: Isoquercetin
Cohort B and Cohort C will take isoquercetin
OTHER: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Memorial Sloan Kettering Cancer C...